These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 31420412)

  • 41. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850).
    Fagotti A; Ferrandina MG; Vizzielli G; Pasciuto T; Fanfani F; Gallotta V; Margariti PA; Chiantera V; Costantini B; Gueli Alletti S; Cosentino F; Scambia G
    Int J Gynecol Cancer; 2020 Nov; 30(11):1657-1664. PubMed ID: 33028623
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
    Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH
    J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
    Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
    Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical significance of primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery in advanced ovarian cancer.
    Nishio S; Ushijima K
    Jpn J Clin Oncol; 2020 Apr; 50(4):379-386. PubMed ID: 32083282
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 3-4 Cycles versus 6 Cycles Neoadjuvant Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: Survival Is Not Determined by the Number of Neoadjuvant Chemotherapy Cycles.
    Bese T; Bicer E; Kayan BO; Cebi SS; Acikgoz AS; Turna H; Demirkiran F
    Chemotherapy; 2024; 69(2):122-132. PubMed ID: 38113873
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer.
    Marrelli D; Petrioli R; Cassetti D; D'Ignazio A; Marsili S; Mazzei MA; Lazzi S; Roviello F
    Surg Oncol; 2021 Jun; 37():101523. PubMed ID: 33545658
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer.
    Makar AP; Tropé CG; Tummers P; Denys H; Vandecasteele K
    Oncologist; 2016 Jun; 21(6):745-54. PubMed ID: 27009938
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
    Angeles MA; Rychlik A; Cabarrou B; Spagnolo E; Guyon F; Pérez-Benavente A; Gil-Moreno A; Siegrist J; Querleu D; Mery E; Gladieff L; Hernández A; Ferron G; Martinez A
    Gynecol Oncol; 2020 Sep; 158(3):614-621. PubMed ID: 32709536
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy.
    Jorgensen K; Melamed A; Wu CF; Nitecki R; Pareja R; Fagotti A; Schorge JO; Ramirez PT; Rauh-Hain JA
    Gynecol Oncol; 2023 May; 172():130-137. PubMed ID: 36977622
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study.
    Nagao S; Tamura J; Shibutani T; Miwa M; Kato T; Shikama A; Takei Y; Kamiya N; Inoue N; Nakamura K; Inoue A; Yamamoto K; Fujiwara K; Suzuki M
    Int J Clin Oncol; 2023 Jun; 28(6):804-815. PubMed ID: 37140771
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial.
    Onda T; Satoh T; Ogawa G; Saito T; Kasamatsu T; Nakanishi T; Mizutani T; Takehara K; Okamoto A; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Kanao H; Watanabe Y; Yamamoto K; Yaegashi N; Kamura T; Yoshikawa H;
    Eur J Cancer; 2020 May; 130():114-125. PubMed ID: 32179446
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of interval between primary cytoreductive surgery with bowel resection and initiation of adjuvant chemotherapy on survival of women with advanced ovarian cancer: a multicenter cohort study.
    Lee YY; Kim SR; Kollara A; Brown T; May T
    J Gynecol Oncol; 2022 Nov; 33(6):e76. PubMed ID: 36047378
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with
    Kim SR; Parbhakar A; Li X; Bernardini MQ; Hogen L; May T
    Int J Gynecol Cancer; 2024 Jun; 34(6):879-885. PubMed ID: 38548312
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery.
    Bizzarri N; Marchetti C; Conte C; Loverro M; Giudice MT; Quagliozzi L; Distefano M; Chiantera V; Scambia G; Fagotti A
    Gynecol Oncol; 2022 Jun; 165(3):453-458. PubMed ID: 35397918
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The importance of the Peritoneal Cancer Index (PCI) to predict surgical outcome after neoadjuvant chemotherapy in advanced ovarian cancer.
    Rawert FL; Luengas-Würzinger V; Claßen-Gräfin von Spee S; Baransi S; Schuler E; Carrizo K; Dizdar A; Mallmann P; Lampe B
    Arch Gynecol Obstet; 2022 Nov; 306(5):1665-1672. PubMed ID: 35357582
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy.
    Tajik P; van de Vrie R; Zafarmand MH; Coens C; Buist MR; Vergote I; Bossuyt PMM; Kenter GG
    Int J Gynecol Cancer; 2018 Mar; 28(3):453-458. PubMed ID: 29324537
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advanced Ovarian Cancer: Weighing the Risks and Benefits of Surgery.
    Kumar A; Cliby WA
    Clin Obstet Gynecol; 2020 Mar; 63(1):74-79. PubMed ID: 31725415
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Neoadjuvant chemotherapy and ovarian cancer].
    Ray-Coquard I; Saba C; Bachelot T; Méeus P; Mignotte H; Blondet R; Treilleux I; Peix M; Guastalla JP
    Bull Cancer; 2006 Jul; 93(7):669-76. PubMed ID: 16873075
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
    Schettino C; Musacchio L; Bartoletti M; Chiodini P; Arenare L; Baldassarre G; Califano D; Capoluongo E; Costi MP; D'Incalci M; Marchini S; Mezzanzanica D; Normanno N; Scala S; Greggi S; Perrone F; Pignata S
    Int J Gynecol Cancer; 2022 Jun; 32(6):799-803. PubMed ID: 35318277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.